Last quarter (Q ), Rasna Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Rasna Therapeutics's net income was $-147.64K. See Rasna Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 23	Sep 22	Sep 21	Sep 20	Sep 19
Total Revenue	-	-	-	$ 72.00K	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	-	$ 72.00K	$ 0.00	$ 0.00
Operating Expense	$ -3.69M	$ 4.24M	$ 141.09K	$ -247.81K	$ 556.50K	$ 915.17K
Operating Income	$ 3.53M	$ -4.24M	$ -383.91K	$ -247.81K	$ -556.50K	$ -915.17K
Net Non Operating Interest Income Expense	$ -224.59K	$ -212.97K	$ -940.99K	$ -515.91K	$ -41.44K	$ -27.57K
Other Income Expense	$ -8.40K	$ -8.85K	$ -263.32K	$ 111.94K	$ -4.75M	$ -1.23K
Pretax Income	$ 3.49M	$ -4.44M	$ -686.59K	$ -332.00	$ -5.35M	$ -943.96K
Tax Provision	$ -278.80K	$ -278.80K	$ -51.20K	$ -90.92K	$ -3.03K	$ -7.58K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 3.49M	$ -4.44M	$ -686.59K	$ -875.67K	$ -5.35M	$ -936.38K
Basic EPS	-	$ -0.01	$ -0.01	$ -0.01	$ -0.08	$ -0.01
Diluted EPS	$ 101.13M	$ -0.01	$ -0.01	$ -0.01	$ -0.08	$ -0.01
Basic Average Shares	$ 2.90B	$ 578.02M	$ 111.43M	$ 68.91M	$ 68.91M	$ 68.91M
Diluted Average Shares	$ 2.90B	$ 578.02M	$ 68.66M	-	$ 68.91M	$ 68.91M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -3.69M	$ 4.24M	$ 141.09K	$ -247.81K	$ 556.50K	$ 915.17K
Net Income From Continuing And Discontinued Operation	$ -4.44M	$ -4.44M	$ -686.59K	$ -875.67K	$ -5.35M	$ -936.38K
Normalized Income	$ -566.36K	$ -4.72M	-	-	$ -597.76K	$ -935.16K
Interest Expense	-	-	-	-	$ 41.44K	$ 27.57K
EBIT	$ 3.72M	$ -4.23M	$ 254.41K	$ 515.58K	$ -5.31M	$ -916.40K
EBITDA	$ 3.90M	$ -4.05M	$ 1.14M	$ 1.06M	$ -5.31M	$ -912.93K

Currency in USD

Rasna Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing